Tripropylamine

Acute Toxicity: other routes

Administrative data

Endpoint:

acute toxicity: other routes

Type of information:

experimental study

Adequacy of study:

supporting study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Acceptable well-documented report which meets basic scientific principles.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1977

Report date:

1977

Materials and methods

Test guideline

Qualifier:

no guideline available

Principles of method if other than guideline:

BASF-Test: The study was conducted according to an internal BASF method. A test group consisting of 5 animals/sex was treated by single injection into the peritoneal cavity. The animals were observed for mortality and for clinical symptoms of toxicity. They were weighed prior to treatment and thereafter, on day 3, 7 and day 13 post-treatment. At the end of the observation period of 14 days, the surviving animals were sacrificed for the purpose of necropsy; animals that died during the observations period also were subjected to necropsy.

GLP compliance:

no

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

Tripropylamine

EC Number:

203-047-7

EC Name:

Tripropylamine

Cas Number:

102-69-2

Molecular formula:

C9H21N

IUPAC Name:

tripropylamine

Test material form:

other: emulsion

Details on test material:

- Name of test material (as cited in study report): Tri-n-propylamin
- Physical state: liquid
- Analytical purity: >= 98%

Test animals

Species:

mouse

Strain:

NMRI

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Weight at study initiation: mean: females: 22.9 g, males: 24.0 g

Administration / exposure

Route of administration:

intraperitoneal

Vehicle:

other: 0.5% carboxmethyl cellulose and 2-3 drops of cremophor EL (v/v)

Doses:

316, 215, 147, 121, 100, 68,1 and 46,4 µL/kg bw
(100 µL test substance corresponds to ca. 75 mg test substance calculated based on the density of the test substance)

No. of animals per sex per dose:

5

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days
- Frequency of observations and weighing: daily observation, weighing was done on day 0, 3, 7 and 13
- Necropsy of survivors performed: yes

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LD50

Effect level:

ca. 75 - 90 mg/kg bw

Based on:

test mat.

Remarks on result:

other: corresponds to 100 - 120 µL/kg bw calculated based on the density of the test substance

Mortality:

316 µL/kg bw: all females and males died one hour after application of the test substance
215 µL/kg bw: 5/5 females and 3/5 males died one hour after application and 2 further males died 24 hours after application of the test substance
147 µL/kg bw: all females and 4/5 males died one hour after application of the test substance
121 µL/kg bw: all animals died one hour after application of the test substance
100, 68,1 and 46,4 µL/kg bw: no animal died within 14 days of observation

Clinical signs:

dyspnoe, apathy, abdominal-lateral position, partly staggering, tremor, tonic-clonic convulsions, exsiccosis, partly exophthalmia, salivation, poor general state

Body weight:

Normal body weight gain was observed.

Gross pathology:

Neither intraabdominal precipitation of the substance nor conglutinations were observed.

Applicant's summary and conclusion

Conclusions:

An intraperitoneal LD50 of 75-90 mg/kg bw was established for rats.

Executive summary:

The study was conducted according to an internal BASF method. A test group consisting of 5 animals/sex was treated by a single injection into the peritoneal cavity. The dose levels were: 316, 215, 147, 121, 100, 68,1 and 46,4 µL/kg bw. The animals were observed for mortality and for clinical symptoms of toxicity. They were weighed prior to treatment and thereafter, on day 3, 7 and day 13 post-treatment. At the end of the observation period of 14 days, the surviving animals were sacrificed for the purpose of necropsy; animals that died during the observations period also were subjected to necropsy. At dose levels of 100, 68,1 and 46,4 µL/kg bw, no animal died within 14 days of observation. The mortality was dose-dependent in animals of the other dose groups. The following clinical signs were noted: dyspnoea, apathy, abdominal-lateral position, partly staggering, tremor, tonic-clonic convulsions, exsiccosis, partly exophthalmia, salivation and poor general state. Normal body weight gain was observed in the surviving animals. Neither intraabdominal precipitation of the substance nor conglutinations were observed at gross pathology. An LD50 of 75 -90 mg/kg bw (corresponds to 100 -120 µL/kg bw) was established based on the density of test material.